Company Overview and News

 
Shares up as Comvita, A2 rebound from weakness, Steel & Tube keeps dropping

20h nzherald.co.nz
New Zealand shares gained as Comvita and A2 Milk Co recovered from selling, while Air New Zealand and Steel & Tube Holdings fell.

 
Shares gain as Ryman posts record profit

2018-05-18 nzherald.co.nz
New Zealand shares rose as Goodman Property Trust's joint venture with GIC sold seven buildings in downtown Auckland, and as Ryman Healthcare chalked up another record profit. A2 Milk Co and Comvita fell.

 
Fletcher Building to announce new Auckland house-building factory next month

2018-05-18 nzherald.co.nz
House construction giant Fletcher Building will announce further details of a new high-tech fast house-building Auckland panelisation factory next month.

 
Stock Takes: A2 fall shows NZ's frailty

2018-05-17 nzherald.co.nz
A2 Milk's plunge on Wednesday shows just how exposed the New Zealand market can be to one stock.

 
Time to reconvene Capital Markets Taskforce?

2018-05-16 nzherald.co.nz
It's time to reconvene the Capital Markets Taskforce and have a clear look at whether more state assets can be primed for partial privatisation through the mixed-ownership model (MOM) and beef up liquidity at the NZX.

 
A2 tumbles, dragging down stock index

2018-05-16 nzherald.co.nz
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.

 
Fletcher Building cuts deal with bankers

2018-05-15 radionz.co.nz
Fletcher Building has cut a new deal with its bankers, which will see it pay more for its lending and put the proceeds of asset sales immediately to paying back debt.

 
Fletcher completes $750M equity raising with sale of shares under retail shortfall bookbuild

2018-05-15 nzherald.co.nz
Fletcher Building has reached its $750 million equity raising target after selling 20.2 million shares under its retail shortfall bookbuild, at a premium price to the entitlement offer but a discount to the trading price of the shares.

 
$53m radio pay day for Lachlan Murdoch

2018-05-15 theage.com.au
And here we were all thinking that the heir apparent, Lachlan Keith Murdoch, was reliant on daddy Rupert Murdoch to earn a crust.

 
$53m radio pay day for Lachlan Murdoch

2018-05-15 smh.com.au
And here we were all thinking that the heir apparent, Lachlan Keith Murdoch, was reliant on daddy Rupert Murdoch to earn a crust.

 
Fletcher Building raises $132 million in retail entitlement offer

2018-05-15 nzherald.co.nz
Fletcher Building said it completed the retail component of its one-for-4.46 pro-rata entitlement offer, raising about $132 million and leaving a shortfall of about $97m to be made up from the retail shortfall bookbuild.

 
MARKET WRAP: MSCI index reshuffle - the winners and losers

2018-05-15 nbr.co.nz
An MSCI index reshuffle sent shares for Fletcher Building soaring after it survived, but Mercury Energy shares fell as it was culled from the index.

 
Shares dip from record; Air NZ and Mercury fall

2018-05-15 nzherald.co.nz
New Zealand shares dipped from a record high, with Air New Zealand and Mercury New Zealand falling while Synlait Milk and Fletcher Building gained.

 
A2 to join MSCI main stock index as Mercury drops off

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.

 
Fletcher gains as stock stays in MSCI main index

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: AN6341605